Laughon, Barbara E.
Nacy, Carol A.
Article History
First Online: 9 March 2017
Competing interests
: C.A.N. is the Founder and CEO of Sequella, Inc., which is the commercial developer of sutezolid and SQ109. B.E.L. declares no competing interests.
Free to read: This content has been made available to all.